Summarized by Masters of Longevity from Longevity Technology.
NKGen’s presentation previews clinical research on an autologous NK cell therapy for dementia, focusing on experimental biomarker and regulatory implications.
Key Takeaways
- NKGen presented clinical data on troculeucel showing changes in cerebrospinal fluid inflammatory markers and disease-associated proteins.
- Troculeucel is an autologous natural killer cell therapy expanded from patient blood and remains investigational without approvals.
- NKGen highlighted Asia's regulatory landscape as a potential faster pathway for initial approval and manufacturing scale considerations.
